12 / 17
Page 64
Journal of Clinical & Experimental Pharmacology | ISSN: 2161-1459 | Volume: 8
International Conference on
July 18-19, 2018 | Atlanta, USA
Pharmacology and Ethnopharmacology
11
th
International Conference and Exhibition on
Pharmaceutical Oncology
&
Pharmacutical scale and green process for the synthesis of anticancer drug Pomalidomide
Reza Hosseinpour
Tofigh Darou Research and Engineering Company, Iran
P
omalidomide (PML), chemically (RS)-4-amino-2-(2,6-dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione, is a small molecule
analog of thalidomide developed by Celgene Corporation for the treatment of hematological and connective tissue diseases by
oral administration. It is a potent second-generation oral immunomodulatory agent with antineoplastic activity, showing significant
activity in multiple myeloma patients with disease refractory to lenalidomide and bortezomib. We develop a new route for the
preparation of pomalidomide on the pharmaceutical scale and polymorphic form based on Celgene Corporation. The synthetic
procedure starts from 4-nitroisobenzofuran-1,3-dione and 3-aminopiperidine-2,6-dione hydrochloride via a 2 step reaction resulting
in a total yield of 95% with a high HPLC purity of 99.98%.
r.h.pour@gmail.comClin Exp Pharmacol 2018, Volume: 8
DOI: 10.4172/2161-1459-C1-029